Data gathered: November 27
Alternative Data for Adaptimmune Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,781 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.
| Price | $0.73 |
| Target Price | Sign up |
| Volume | 3,290,000 |
| Market Cap | $178M |
| Year Range | $0.59 - $1.58 |
| Dividend Yield | 0% |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
 |
GSA Capital Partners LLP Makes New $95,000 Investment in Adaptimmune Therapeutics plc (NASDAQ:ADAP)November 26 - ETF Daily News |
|
HC Wainwright Analysts Increase Earnings Estimates for ADAPNovember 19 - ETF Daily News |
 |
Guggenheim Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock PriceNovember 18 - ETF Daily News |
|
Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Rating Lowered by StockNews.comNovember 17 - ETF Daily News |
 |
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 15 - Yahoo |
|
Adaptimmune Therapeutics Presents Positive Data from Phase 2 IGNYTE-ESO Trial at CTOS 2024 Annual MeetingOn November 13, 2024, Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed significant data from the primary analysis of its pivotal Phase 2 IGNYNovember 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 41M | 21M | 20M | -18M | 0 | -0.010 |
| Q2 '24 | 128M | 19M | 109M | 70M | 69M | 0.240 |
| Q1 '24 | 5.7M | 20M | -14M | -49M | -49M | -0.180 |
| Q4 '23 | 740,000 | 19M | -18M | -48M | -51M | -0.240 |
| Q3 '23 | 7.3M | 16M | -8.8M | -46M | -46M | -0.200 |
Insider Transactions View All
| Piccina Cintia filed to sell 38,293 shares at $0.9. June 18 '24 |
| Bertrand William C JR filed to sell 7,785 shares at $0.7. January 17 '24 |
| Lunger John filed to sell 7,785 shares at $0.7. January 17 '24 |
| Norry Elliot filed to sell 7,785 shares at $0.7. January 17 '24 |
| Bertrand William C JR filed to sell 20,201 shares at $0.7. January 17 '24 |
Similar companies
Read more about Adaptimmune Therapeutics (ADAP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Adaptimmune Therapeutics?
The Market Cap of Adaptimmune Therapeutics is $178M.
What is the current stock price of Adaptimmune Therapeutics?
Currently, the price of one share of Adaptimmune Therapeutics stock is $0.73.
How can I analyze the ADAP stock price chart for investment decisions?
The ADAP stock price chart above provides a comprehensive visual representation of Adaptimmune Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptimmune Therapeutics shares. Our platform offers an up-to-date ADAP stock price chart, along with technical data analysis and alternative data insights.
Does ADAP offer dividends to its shareholders?
As of our latest update, Adaptimmune Therapeutics (ADAP) does not offer dividends to its shareholders. Investors interested in Adaptimmune Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Adaptimmune Therapeutics?
Some of the similar stocks of Adaptimmune Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.